Shots:
Nirja gave the details of the PATHWAY anti-HER2 (4B5) to identify metastatic breast cancer patients with low HER2 expression through its scoring algorithm that helps pathologists to identify “low expressors” of HER2
She told PharmaShots about how this test is able to identify patients who may benefit from Enhertu as a treatment option. She…
Shots:
Iris shared the specifics of the launch of the UCB’s Innovators campaign. The campaign spotlights the R&D employees’ perspectives on innovation and aims to highlight why innovation is a key driving force at UCB for bettering the lives of patients
She gave her thoughts on how UCB is adopting innovative AI programs that use…
Shots:
Jason shared his views on the launch of Metabolon, Inc.’s new Oxysterols Targeted Panel, highlighting its key features
He told how the panel measures 12 oxysterols and related sterols of biological significance to identify biomarkers for the prediction and early detection of cardiovascular diseases, neurodegenerative diseases, and cancer
The interview gives a profound understanding…
Shots:
Zack Usilton spoke about their partnerships with Reston ENT. He also elaborated on their past collaborations with some of the allergy groups
He also spoke on how these alliances will help Senta Partners to expand its footprint across 57 locations in 5 states in the Mid-Atlantic region
The interview gives an understanding of Senta…
Shots:
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency
Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients
During the month of February, Alvotech entered into a commercialization agreement…
Shots:
Laura gave an overview of Human acellular vessels (HAV). She talked about the six-month results of the HAV in a non-human primate model of CABG presented at the annual American Heart Association (AHA) Scientific Sessions 2022
She also elaborated on the construction and development of the CABG model and how it treats blocked arteries…
Shots:
Steffen shared the details of the first patient enrolled in the P-II study of Aphaia Pharma’s lead product APH-012 to induce weight loss in individuals with obesity
He briefed the PharmaShots team about the study design of the P-II trial and also elaborated on the results from the P-I study
The interview shows how…
The 15th and 16th of February saw the Global PHT Expo & Summit taking place at the Hyatt Centric in New Delhi, India.
Through Global PHT Summit, it was for the first time that the pharma, healthcare, and technology veterans, pioneers, and professionals converged on the same platform to impart their knowledge on the best & futuristic PHT practices. The theme of the event…
Shots:
The EMA approved 3 New Chemical Entity (NCE) and 5 Biologic Drugs in January 2023, leading to treatments for patients and advances in the healthcare industry
In January 2023, the major highlights drugs were Xofluza’s Approval for influenza, Dupixent for eosinophilic esophagitis
PharmaShots has compiled a list of a total of 8 new drugs…
Active Ingredient: dulaglutide
Dosage Forms & Strengths:
Injection: 0.75 mg/0.5 mL, 1.5 mg/0.5 mL, 3 mg/0.5 mL, 4.5 mg/0.5 mL solution in a single-dose pen
Mechanism of Action: GLP-1 receptor agonist
First Approval: US (Sep 18, 2014), EU (Nov 25, 2014)
Revenue Analysis1
Trulicity is used for the treatment of type 2 diabetes and to reduce the risk…

